Pregabalin add-on for Neuropathic Pain in Cervical Myelopathy

• Status: Unknown status
• Trial end date: 2019-12-31
• Target enrollment: 0
• Participant gender: All

Summary

There is no information on the effect of pregabalin in patients with neuropathic pain in cervical myelopathy under routine clinical practice.

The investigators will conduct this prospective, randomized trial to determine the efficacy of pregabalin for neuropathic pain in cervical myelopathic patients in order to validate or refute this popular practice. The primary aim of this study was to compare Leeds assessment of neuropathic symptoms and signs scale (LANSS) scores of neuropathic pain in cervical myelopathy patients.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Seoul National University Hospital
• Treatments: Analgesics, Opioid; Pregabalin

Criteria

Inclusion Criteria:

1. between the ages of 18 to 80 years

2. Among patients with cervical myelopathy, patients with neuropathic pain (LANSS pain scale ≥ 12)

3. Completing 8-week drug trial

Exclusion Criteria:

1. Current or prior gabapentin or pregabalin use

2. Chronic use of narcotic pain medications

3. Chronic depression or the use of anti-depressants

4. History of addiction and/or substance abuse

5. Presence of significant motor deficits, and /or bowel and/or bladder dysfunction

6. Known renal insufciency, diabetes, congestive heart failure, cardiac conduction abnormalities, and thrombocytopenia